Conditions: Colorectal Cancer
Keywords: Open-label dose escalation BRAF inhibitor LGX818 PI3K inhibitor BYL719 EGFR cetuximab metastatic colorectal cancer KRAS BRAF V600
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 156
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: LGX818 intervention 2: Cetuximab intervention 3: BYL719
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: